Priority 13 from the Hidradenitis Suppurativa PSP
| UNCERTAINTY: How effective are oral treatments that affect the immune system (eg. Dapsone, ciclosporin, methotrexate, prednisolone) in treating Hidradenitis Suppurativa? (JLA PSP Priority 13) | |
|---|---|
| Overall ranking | 13 |
| JLA question ID | 0017/13 |
| Explanatory note | Not available for this PSP |
| Evidence |
Systematic Review: Blok JL, van Hattem S, Jonkman MF, Horváth B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. British Journal of Dermatology. 2013 Feb;168(2):243-52. doi: 10.1111/bjd.12104~PMID: 23106519 |
| Health Research Classification System category | Skin |
| Extra information provided by this PSP | |
|---|---|
| Comparison | Drug |
| Submitted by | 15 patients, 75 clinicians |
| Outcomes to be measured | Management and or change of symptoms (pain, Hidradenitis Severity Score, time to remission and duration of remission, physician and patient assessment of change ); adverse effects* (morbidity, hospital admission), or complications (adverse effects leading to treatment discontinuation ,increased duration of treatment); acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life*; and health related costs. *Signifies Primary outcomes |
| PSP information | |
|---|---|
| PSP unique ID | 0017 |
| PSP name | Hidradenitis Suppurativa |
| Total number of uncertainties identified by this PSP. | 55 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 6 December 2013 |